Trial site
Teikyo University Hospital
tabashi City, 173 8606, JapanNot linked to an institution yet
- 17running trials
- 13closed trials
The trials here
What the 30 trials at this site are about, from their registry records.
- Phase
- Phase 317 trials
- Phase 11 trial
- Phase 21 trial
- Phase 2/31 trial
- Phase 41 trial
- Status
- Completed13 trials
- Active, not recruiting11 trials
- Recruiting6 trials
- Lead sponsor
- Janssen Research & Development, LLC7 trials
- Amgen4 trials
- Janssen Pharmaceutical K.K.3 trials
- Takeda3 trials
- Bristol-Myers Squibb2 trials
- and 10 more
Running trials
Active, not recruiting
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
NCT07230860· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Clinical Evaluation of AMJ-401
NCT07373353· Abbott Medical Devices· Source
Recruiting
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
NCT07250802· Phase 3· Takeda· Source
Contact: Yayoi Tada (principal investigator)
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967· Phase 3· Bristol-Myers Squibb· Source
Contact: Yayoi Tada, Site 0391
Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433· Phase 3· Amgen· Source
Recruiting
Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure
NCT07125417· Phase 4· OCEAN-SHD Study Group· Source
Contact: Yusuke Watanabe
Recruiting
Prevail Global Study
NCT06535854· Medtronic Vascular· Source
Contact: Yusuke Watanabe (principal investigator)
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
NCT06531109· Pfizer· Source
Active, not recruiting
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
NCT06295692· Phase 3· Janssen Pharmaceutical K.K.· Source
Active, not recruiting
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT06143878· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565· Phase 2/3· Biogen· Source
Recruiting
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
NCT04951622· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT04772079· Phase 3· Bristol-Myers Squibb· Source
Contact: Yayoi Tada, Site 0034
Active, not recruiting
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
NCT03950232· Phase 3· Pfizer· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study
NCT06412848· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source
Completed
A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
NCT06323356· Phase 3· Takeda· Source
Completed
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
NCT06088043· Phase 3· Takeda· Source
Completed
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957· Phase 3· Janssen Research & Development, LLC· Source
Completed
A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis
NCT05565560· Phase 3· Amgen· Source
Completed
A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)
NCT05398445· Phase 3· Amgen· Source
Completed
Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)
NCT05174065· Phase 3· Amgen· Source
Completed
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer
NCT06542731· Phase 1· Ono Pharmaceutical Co., Ltd.· Source
Completed
A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan
NCT04459507· Janssen Pharmaceutical K.K.· Source
Completed
Registry of Asthma Patients Initiating DUPIXENT®
NCT04287621· Regeneron Pharmaceuticals· Source
Completed
Safety and Effectiveness of Agent Paclitaxel-Coated PTCA Balloon Catheter. (AGENT Japan SV)
NCT04058990· Boston Scientific Corporation· Source
Completed
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
NCT04034095· Janssen Pharmaceutical K.K.· Source
Completed
Clinical Trial of Cilostazol Eluting Stent System (CES-1) in De Novo Coronary Artery Lesions
NCT03189641· JIMRO Co., Ltd.· Source
Report an error